Myroides species, pathogenic spectrum and clinical microbiology sight in Mexican isolates Authors: Claudia Adriana Colín-Castro, Jossue Mizael Ortiz-Álvarez, Cindy Fabiola Hernández-Pérez, Melissa Hernández-Durán, María de Lourdes García-Hernández, María Guadalupe Martínez-Zavaleta, Noé Becerra-Lobato, Mercedes Isabel Cervantes-Hernández, Graciela Rosas-Alquicira, Guillermo Cerón-González, Braulio Josué Méndez-Sotelo, Rodolfo García-Contreras, Rafael Franco-Cendejas, Luis Esaú López-Jácome, Mabel Kamweli Aworh, Mabel Kamweli Aworh, Mabel Kamweli Aworh Published: 2024 ABSTRACT IntroductionMyroides is a bacterial genus of opportunistic bacteria responsible for diverse infections including in the skin and soft tissues, urinary tract, cardiovascular system, and bacteremia, although the incidence of its reported infections is low, it is increasing, likely due the use of better bacterial identification methods, but also perhaps due an increase in its prevalence. In addition, their pathogenic role is limited in terms of reporting their microbial physiology, so the present work provides information in this regard in addition to the information that is available in the international literature.ObjectiveTo describe the microbiological and genetic characteristics of seven different Myroides spp. clinical strains and comment on their phylum, pathogenic and resistance characteristics.MethodsSeven Myroides spp., strains associated with infections were included from 1/January/2012 to 1/January/20 and identified by miniaturized biochemistry and MALDI-ToF. Susceptibility tests were performed according to CLSI recommendations by broth microdilution. Whole genome sequencing was performed for each strain and bioinformatics analysis were performed.ResultsStrains were identified at genus level by two methodologies. Our results revealed that likely four strains belong to the species Myroides odoratimimus, while the other two may be undescribed ones. Remarkably, all isolates harbored several genes encoding antibiotic resistance determinants for ß-lactams, aminoglycosides and glycopeptides and in concordance, presented high levels of resistance, against these antibiotics (AK and GN both 100%, ATM, CAZ and FEP 100%, e.g.); moreover, the presences of carbapenemases were evidenced by meropenem (mCIM) and imipenem (CARBA NP) degrading activity in six isolates and two strains possessed plasmids harboring mainly ribosomal RNA genes, tRNAs and genes encoding proteins with unknown functions.ConclusionsOur study increases the knowledge about the biology of this understudied genus and highlights the potential of Myroides to emerge as a broader cause of recalcitrant opportunistic infections. Introduction The genus Myroides, first isolated in 1923 in feces of patients with gastrointestinal infections [1], belongs to phylum Bacteroidota, class Flavobacteriia, order Flavobacteriales and family Flavobacteriaceae. Myroides is comprised of 13 species in NCBI Taxonomy Browser, which comprise Myroides albus, Myroides fluvii, Myroides gitamensis, Myroides guanonis, Myroides indicus, Myroides injenensis, Myroides marinus, Myroides odoratimimus, Myroides odoratus, Myroides oncorhynchi, Myroides pelagicus, Myroides phaeus and Myroides profundi [2, 3]. Myroides was initially included within Flavobacterium genus, specifically Flavobacterium odoratum and described by Stutzer in 1929, however, Vancanneyt and coworkers reclassified it and created a new genus, Myroides [4]. The given name came from Greek noun mýron which means perfume and Latin suffix oides means similar, shape, form or resembling (used in taxonomy), therefore Myroides resembling perfume, this due to the sweet odor, like fruits, characteristics in this genus [5]. It is an aerobic strict, thus is positive for oxidase and catalase activity, Gram-negative rod, 0.5 x 1–2 μm, non-motile, including gliding. Growing conditions characterizes its ability to grow on MacConkey agar and non-hemolysis production, growth at 18–22° C, and 37° C. Myroides produces, in the most of times, yellow or orange colonies [5]. Clinically, only four species of Myroides (M. odoratimimus, followed by M. odoratus. M. injenensis and M. phaeus) have been related with different infections such as endocarditis, pericarditis, urinary tract infections, skin and soft tissue infections, ventriculitis, liver abscesses and bacteremia, either in immunocompromised or immunocompetent host, as well [6–9]. The number of reported infections by Myroides species have been documented in a major frequency due the employment of more sensible and reliable techniques, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 16S ARN sequencing; Myroides species have been reported specially in hospital outbreaks causing catheter related urinary tract infections [10, 11] associate, probable, to some factors such as prolonged use of antibiotics, immunosuppression, and invasive procedures [12]. Furthermore, it is linked to multiple antimicrobial resistance mechanisms [13]. However, as data expands, there must be more species associated with different infections that might be added, in this sense, information, either microbiological or genetic, is limited and impact of Myroides spp., infections are not well understood, therefore, the role of infections is poorly documented. The aim of this work was to describe the microbiological and genetic characteristics of seven different Myroides spp. clinical strains and comment on their phylum, pathogenic and resistance characteristics. Material and methods Clinical strains We conducted a retrospective study seeking Myroides spp., isolates from a tertiary care Hospital in Mexico City. We included all strains isolated from invasive samples, including blood cultures, lower respiratory samples, abscesses, and tissue biopsies, over an eleven-year period from 1/January/2012 to 1/January/2023 and were accessed for research on 15/May/2023. Duplicated samples were excluded. The collection and sample processing were conducted at Clinical Microbiology Laboratory at Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra in Mexico City. All isolates were stored at -70°C and subsequently inoculated onto 5% sheep blood agar prior to their use. Identification at the beginning was performed with the Vitek 2 compact (BioMérieux, Marcy ′Étoile, France) and was confirmed with Vitek MS (MALDI-ToF, (BioMérieux, Marcy ′Étoile, France)) following manufacturer’s recommendations. Information from clinical records was obtained. Current work only involves clinical strains obtained by the typical procedures and guidelines, however, the strains used, and the experimental plan was approved by the research committee of the Institute with the assigned number 55/22 AC. Minimal inhibitory concentrations determination The antibiotics evaluated were: Amikacin (AK), Gentamicin (GN), Aztreonam (ATM), Ceftazidime (CAZ), Cefepime (FEP), Ciprofloxacin (CIP), Levofloxacin (LVX), Meropenem (MEM), Imipenem (IMP), Colistin (CL), Piperacillin/Tazobactam (TZP), azithromycin (AZT), Erythromycin (E), Doxycycline (DO), Tigecycline (TYG) and Sulfamethoxazole/trimethoprim (SXT) (Sigma Aldrich, Burlington, Massachusetts, USA). Broth microdilution assay was performed following the recommendations by the CLSI [14]. E. coli ATCC 25922 was used for quality control. Due breakpoints are not defined for Myroides spp., neither in CLSI or EUCAST MIC was defined as the lowest concentration that inhibits bacterial growth. For AK, GN, ATM, CAZ and FEP concentrations tested were from 256 μg/mL to 0.25 μg/m, while for CIP, LVX, MEM, IMP, AZT, E, DOX, and TYG concentrations were 64 μg/mL to 0.0612 μg/mL. On the other hand, for COL and TZP were 128 μg/mL to 0.125 μg/mL and 128/4 μg/mL to 0.125/4 μg/mL respectively. Finally, SXT starting concentration 8/152 μg/mL to 0.00078/0.1484 μg/mL. Phenotypic test to determine carbapenemase activity Carbapenemase test was performed for each sample according to CLSI M100 2023 recommendation [14]. First, modified carbapenem inactivation method (mCIM) was carried oud, briefly, colonies were harvested with a 10 μL loop and deposited into a 2 mL polypropylene tube with 1.5 mL Trypticase soy broth, then a 10 μg MEM disc added into the tube. The tubes were incubated during 4 h at 37° C. After that, E. coli ATCC 25922 pan susceptible at 0.5 McFarland Scale was inoculated onto Mueller-Hinton plates. The same strain of E. coli ATCC 25922 was used as negative control and Klebsiella pneumoniae ATCC BAA-1705 as positive control (carbapenemase producer). The interpretation of the test was according to CLSI M100 2023 [14]. Due this method is validated just for Enterobacterales and Pseudomonas aeruginosa, a second method was performed, CARBA NP, also referred in CLSI M100 2023, briefly, two 600 μL conic tubes were labelled for each strain tested, then 100 μL of protein extraction buffer were added to each tube (a and b) and vortexed for 5 seconds and subsequently 100 μL of solution A (without IMP as substrate) and B (supplemented with IMP as substrate to carbapenemase) were added to the respective tubes labelled and again vortexed and incubated at 35° C/2 hours. Positive tests showed a change in color (yellow as positive and unchanged as negative). E. coli ATCC 25922 was used as negative control and K. pneumoniae ATCC BAA-1705 as positive control. The interpretation of the test was according to CLSI M100 2023 [14]. Whole genome sequencing Genomic DNA was extracted with DNeasy Blood & Tissue (QIAGEN). Once extracted, DNA quality and concentration were determined with the Qubit 3.0 fluorometer (Invitrogen, USA) and the Nanodrop One/One spectrophotometer (Thermo Fisher Scientific, USA) and samples were kept at -20°C, until use. Library preparation was performed using the Illumina DNA Prep (Illumina, USA) for the tagmentation, indexing and cleaning steps, as well as the employment of IDT for Illumina DNA/RNA UD Indexes (Illumina, USA) for the indexing step. Library quality control was performed using the Qubit 3.0 fluorometer (Invitrogen, USA) and the 4200 Tapestation System (Agilent, USA). Sequencing of pooled and normalized libraries was made using the MiSeq Reagent Kit V2 (300 cycles) on the Illumina MiSeq platform in a paired end configuration. Samples were sequenced at Centro Nacional de Referencia de Inocuidad y Bioseguridad Agroalimentaria from Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria [15]. Plasmid extraction and purification In addition, plasmids were searched in all strains included. Plasmids were isolated and purified with the E.Z.N.A Plasmid DNA Mini Kit I (Omega bio-tek, Norcross, Georgia, USA). Once extracted, 5 μL of DNA were run in 1% agarose gel and visualized through Gel Doc XR+ with Image Lab Software (Bio-Rad; Hercules, California, USA), a 100 bp molecular ladder was used (Invitrogen; Waltham, Massachusetts, USA). Plasmid library preparation and sequencing were performed in the same manner as for genomic DNA [15]. Genomic analysis The Quality of the Sequenced Read Archives (SRA) generated was analyzed by using FastQC [16]. The removal of contaminations and sequences with poor Phred values <30 was conducted with Trimmomatic [17]. The SRA of each strain were assembled with SPAdes [18]. Each assembling quality were determined with QUAST [19]. The contigs of each genome were subject to the removal of sequences with coverage values <200 by using the seqtk_seq included in the sektq package [20]. A general annotation for the contigs was performed with Prokka [21]. The evaluation of the annotation based on completeness determination was conducted by using BUSCO [22]. A preliminary identification of the strains was performed with the generation of a phylogenetic tree based on the analysis of partial 16S rRNA. The sequences belonging to the 16S rRNA gene of each sequenced genome for this study were extracted by using barrnap [23]. The sequences of type strains were obtained from the non-redundant GenBank database [24]. A multiple sequence alignment (MSA) of 16S sequences was obtained with MUSCLE [25]. The Maximum Likelihood (ML) phylogeny was constructed in IQTREE employing the TVM + F + I + G4 evolutionary model with Ultrafast-Bootstrap determination of 10,000 replicates [26]. The 16S-based phylogenetic trees were edited and visualized with iTOL v5 [27]. As complementary, pairwise gene identity scores were determined with Protologger [28]. The annotation of Antimicrobial Resistance Elements (ARE) was conducted with Abricate [29], by using the Comprehensive Antibiotic Resistance Database (CARD) [30]. The annotation of the virulence factors (VF) was performed by using Markov Hidden Models with HMMER package [31] and custom scripts, based on the VF identified for M. odoratimimus [32]. The plasmids were extracted and typed with MOB Suite [33]; annotated and visualized with Proksee web server [34]. Results Strains included During the study period, a total of seven strains previously identified such as Myroides spp., which were confirmed with Vitek 2 compact and with Vitek MS, such as Myroides spp. Four isolates affected males, five cases were associated with skin and deep tissue infections as showed in Table 1. 10.1371/journal.pone.0310262.t001Table 1Clinical characteristics, treatment given, and outcomes of clinical strains included.NumberGender/ Age (years)ComorbiditiesType of infectionClinical sampleIsolation DateTreatmentOutcomeEB1487Male / 17Congenital scoliosisCatheter related Urinary tract infectionUrine23/04/2014CiprofloxacinCuredC1519Female / 37Spinal cord injury and traumaOsteomyelitisBone biopsy06/08/2015MeropenemCuredC1996Female / 41Burn injurySkin and Soft tissue infectionQuantitative biopsy (skin)14/11/2016MeropenemDied / Other infectionsC2723Male / 11TraumaSkin and Soft tissue infectionQuantitative biopsy (skin)29/11/2018AmikacinCuredC4067Male / 8TraumaSkin and Soft tissue infectionQuantitative biopsy (skin)15/07/2021CiprofloxacinCuredC4256Male / 24Burn injuryOsteomyelitisBone biopsy28/09/2021MeropenemCuredC4411Female / 48EpendymomaCatheter related urinary tract infectionUrine09/12/2021None (catheter changed)Cured Clinical characteristics, treatment given, and outcomes of clinical strains included. Treatment chosen was different for each strain including fluoroquinolones, aminoglycosides and carbapenems, meanwhile for osteomyelitis the antimicrobial selected was meropenem, with different time periods depending on the type of infection. Susceptibility patterns The greatest resistance rates were observed for aminoglycosides (AK and GN) with MICs ≥ 256 μg/mL, followed by ß-lactams (ATM, cephalosporins and TZP). On the other hand, azithromycin had lower MICs (around 2 μg/mL the most) in comparison with erythromycin which had the higher concentration with 4 μg/mL and the lowest with 0.5 μ/mL; however, tetracyclines showed similar MICs between members assessed. The lowest MICs observed in antibiotics evaluated were in SXT as reported in Tables 2 and 3. 10.1371/journal.pone.0310262.t002Table 2Myroides spp. minimum inhibitory concentrations of clinical strains.StrainAK (μg/mL)GN (μg/mL)ATM (μg/mL)CAZ (μg/mL)FEP (μg/mL)CIP (μg/mL)LVX (μg/mL)MEM (μg/mL)IMP (μg/mL)COL (μg/mL)TZP (μg/mL)EB1487256> 256128256644444> 128128/4C1519> 256> 25664128320.50.584> 128128/4C1996> 256> 25625625664643222> 128128/4C2723256642566482410.25> 12832/4C4067> 256> 256256256642284> 128128/4C4256> 256> 256256256642284> 128128/4C4411> 256> 256256256642284> 128128/4AK: amikacin; GN: gentamicin; ATM: aztreonam; CAZ: ceftazidime; FEP: cefepime; CIP: ciprofloxacin; LVX: levofloxacin; MEM: meropenem; IMP: imipenem; COL: colistin; TZP: piperacillin/tazobactam Myroides spp. minimum inhibitory concentrations of clinical strains. AK: amikacin; GN: gentamicin; ATM: aztreonam; CAZ: ceftazidime; FEP: cefepime; CIP: ciprofloxacin; LVX: levofloxacin; MEM: meropenem; IMP: imipenem; COL: colistin; TZP: piperacillin/tazobactam 10.1371/journal.pone.0310262.t003Table 3Myroides spp. minimum inhibitory concentrations.StrainAZT (μg/mL)E (μg/mL)DOX (μg/mL)TIG (μg/mL)SXT (μg/mL)EB1487140.521/19C151910.50.12510.5/9.5C199624221/19C27230.520.50.252/38C40672210.51/19C42562410.51/19C44112210.52/38AZT: azithromycin; DOX: doxycycline; E: erythromycin; TIG: tigecycline; SXT: sulfamethoxazole/trimethoprim. Myroides spp. minimum inhibitory concentrations. AZT: azithromycin; DOX: doxycycline; E: erythromycin; TIG: tigecycline; SXT: sulfamethoxazole/trimethoprim. Phenotypic test to determine carbapenemase activity Due to high MICs values for ß-lactam antibiotics, including carbapenem, we performed phenotypic assay looking for carbapenemases presence according to CLSI guidelines M100, however, this procedure is not yet validated and standardized for microorganisms different to Enterobacterales or Pseudomonas aeruginosa. We identified hydrolytic activity against MEM in EB1487, C1519, C4411 with halos < 15 mm, on the other hand, C1996 and C4256 had halos with 16 mm, according CLSI M100 definitions, for Enterobacterales and Pseudomonas aeruginosa this measure corresponds with the definition of inconclusive. However, with CARBA NP strain C1996 was interpreted as positive as well as C4256. Previously C4067 was defined to be negative with mCIM however, once repeated with CARBA NP was defined as positive (S1 Fig). While the rest of the strains had halos > 19 mm (negative); however, as mentioned above, this is not a validated strategy for this microorganism, so the negative result could be due to a limitation of the strategy. Molecular identification The phylogenetic tree reconstructed exhibited the following: four strains (C4366, EB1487, C4411 and C1996) were clustered with M. odoratimimus type strain, with an identity percentage > 99% (Fig 1), in Table 4 are included all those non-repeated sequences downloaded to build the phylogeny. Hence, the results indicate that these four strains may be identified as M. odoratimimus. By the other hand, the strain C4067 evidenced a phylogenetic relationship with Myroides marinus, however, they shared a 95.67% of identity. Likewise, the strains C2723 and C1519 were clustered in the same clade with Myroides phaeus, showing a 96.3% of identity among them; consequently, we suspect the strains of Myroides C4067, C2723 and C1519 may be cataloged as new species. ML phylogenetic tree of the 16S rRNA sequences. The strains evaluated in this study are marked in bold blue color into the tree. Numbers on the nodes and branches represent the Ultrafast Bootstrap values of 10,000 replicates. Scale bar represents the number of nucleotide differences between branches. 10.1371/journal.pone.0310262.t004Table 4Sequences of study for ML phylogenetic tree reconstruction.OrganismGenBank ID Myroides odoratus M58777 Myroides fluvii MK129421 Myroides pelagicus AB176662 Myroides albus MK734183 Myroides injenensis HQ671078 Myroides phaeus GU253339 Myroides oncorhynchi OL437262 Myroides profundi EU204978 Myroides odoratimimus AJ854059 Myroides gitamensis HF571338 Myroides marinus GQ857652 Flavobacterium olei KX672808 Flavobacterium azizsancarii OQ024221 Flavobacterium soyangense KX061439 Flavobacterium dasani MH019224 Flavobacterium aquaticum HE995762 Flavobacterium vireti KM576853 Flavobacterium inkyongense KX025140 Flavobacterium fulvum KU052686 Flavobacterium yanchengense JX548325 Flavobacterium ardleyense KX911209 Flavobacterium aquimarinum KY612936 Flavobacterium ponti GQ370387 Flavobacterium shanxiense KJ641612 Cytophaga massiliensis EF394924 Flavobacterium naphthae MF405102 Myroides cloacae KU746272 Myroides anatoliensis JF825522 Sequences of study for ML phylogenetic tree reconstruction. Virulence Factors (VF) and Antimicrobial Resistance (AMR) genes detection A total of 15 elements associated with VF and classified in seven categories were recognized and annotated. The summary of this result is displayed in Fig 2. All elements were identified in all strains, nevertheless sodB (encoding for Superoxide dismutase) was not identified in the isolates C1519 and C2723, whereas wecC, encoding for UDP-N-acetyl-D-mannosaminuronic acid dehydrogenase was not detected in the isolate EB1487. The VF recognized maybe associated with production of capsular polysaccharide, cell wall peptidoglycan, heme biosynthesis (oxidative respiration), intracellular survival factors (ISF), chaperones, streptococcal enolase and type 4 secretion system effectors (T4SS effectors). Virulence factors found in clinical strains of Myroides spp. Also 8 kinds of elements associated with Antibiotic Resistance (ARE) were detected (Fig 3). The strains showed an average of about 15 AMR genes, exhibiting an evident multidrug resistance and harboring high diversity of AREs. The isolate Myroides spp. C4067 presented the highest diversity and content of AREs, with a total of 22 genes. On the other hand, the strain Myroides spp. C2723 exhibited the lowest content of AMR genes. In general, the drug class assigned for the AMR genes identified was congruent with the MIC profiles obtained in experimental assays. Even though the tet(X2) gene was identified in two strains, these displayed susceptibility to tetracyclines. Also, the iri and rphA, linked with rifampicin resistance were detected. The strains exhibited a significant abundance of AREs associated with ß-lactam, aminoglycosides, and glycopeptides resistance, matching with the resistance profiles to this antibiotic observed. Interestingly, all strains showed the presence of ereB, an erythromycin esterase-like associated with resistance to macrolides, despite the strains being susceptible to azithromycin. Interestingly, strains with GOB-16, a metallo ß-lactamase, were C4256, EB1487, C4067, C4411, these same strains shared another metallo ß-lactamase belonging to the IMP family (IMP-27), strain C1996 carried IMP-27 but not GOB-16. On the other hand, strains C4411 and C4256 co-carried two IMPs (IMP-27 and IMP-35) in addition to GOB-16. MUS-1 is a metallo ß-lactamase identified in Myroides present in almost all isolates except C2723 and C1519. Of the members of the oxacillinase (OXA) family with carbapenemase activity we found OXA-229 (C4411, C4067 and C4256), OXA-351 (C4067) and OXA-97 (C4256). Of the AmpC group, PDC-85 was found in C2723 and C1519. Genes associated with colistin resistance were found in mcr3.10, mcr3.6 and mcr3.7. Strains C1996, C4256, C4067 shared the presence of mcr3.6 and mcr3.7 genes. EB1487 co-carried mcr3.10 and mcr3.6 while C4411 carried only mcr3.7. Phenotypically, EB1487, C1519 and C4411 showed carbapenemase activity against meropenem. Antimicrobial resistance elements presents in Myroides species strains. Plasmid identification and annotation Two plasmids were detected (S2 Fig) in the strains Myroides spp. C2723 (Plasmid ID C2723_C6) (Fig 4) and M. orodatimimus EB1487 (Plasmid ID EB1487_S7) (Fig 5). The C2723_C6 showed an approximate size of 19 Kb, whereas EB1487_S7 exhibited a size of 150 Kb. Therefore, we consider EB1487_S7 as a megaplasmid. The annotation of the plasmid showed that C2723_C6 harbors ribosomal RNA genes, as well as tRNA sequences. A total of 11 proteins were predicted, however, the annotation assigned them as hypothetical proteins. Genomic map of the identified plasmid pM2723. The inner circle represents the genome size per region. The outer circle marks all open reading frames and proteins predicted. Forms and letters in purple show the location of ribosomal RNA genes. Forms and letters in orange indicate the location of tRNA genes. Forms and letters in blue indicate the location of annotated and unannotated proteins. Genomic map of the identified plasmid EB1487_S7. The inner circle represents the genome size per region. The outer circle marks all open reading frames and proteins predicted. Forms and letters in purple show the location of ribosomal RNA genes. Forms and letters in orange indicate the location of tRNA genes. Forms and letters in blue indicate the location of annotated and unannotated proteins. By the other hand, the EB1487_S7 also harbored ribosomal RNA and tRNA genes, and 101 proteins were predicted, of which 75 were cataloged as hypothetical proteins. Twenty-six genes were properly annotated for EB1487_S7 whose functional classification may be associated with mobile elements, DNA processing, amino acid metabolism, aerobic respiration, cell wall peptidoglycan biosynthesis, carbon metabolism, ROS defense, and membrane transport. Discussion Since the reclassification of Flavobacterium odoratum and the creation of the new genus Myroides by Dr. Vancanneyt M et al. in 1996 [4], very little evidence has been generated on the role of Myroides associated with infections in patients, only 43 articles were found in PubMed since 2000 using the search terms "Myroides" and "infection". Of these, bacteremia and urinary tract infection were the most frequent. The most common species were M. odoratimimus and M. odoratus [6–8, 10, 11, 35–71] Myroides species are typically found in immunocompromised hosts, although there have been a few cases reported in immune competent individuals [6, 68, 69]. In our series, skin, and soft tissue infections, as well as deep infections, were the most common. This is likely since we are a tertiary care hospital specializing in orthopedics, rehabilitation, and burns. Except for one patient, all were successfully treated despite having various comorbidities. The deceased patient had burn injuries and was infected with Myroides, along with other Gram-negative bacteria. Burn patients are severely immunosuppressed, making them more susceptible to infections due to the loss of their skin barrier. No previous cases of Myroides infection have been reported in burned patients. The identification of rutinary cultures within a clinical microbiology lab is performed with miniaturized biochemistry systems such as Vitek 2 [72] (BioMérieux, Marcy ′Étoile, France) and Phoenix (Becton-Dickinson, New Jersey, USA) [43]. The introduction of instruments with larger databases and better precision and sensitivity, such as MALDI-ToF, has increased detection capacity, but even these types of systems, have methodological limitations for a suitable discrimination among species [73, 74]. Therefore, we recurred to a presumptive molecular identification of pathogens based on phylogenetic analysis of 16S rRNA. The phylogenetic reconstruction has been useful for other studies for resolving properly the identity of isolates belonging to Stenotrophomonas genus [15]. The use of 16S analysis as a robust tool for identification in the clinical routine is not common [75], but has been widely explored in clinical research studies for a presumptive assignment of identity to bacteria species [76–79]. According to the criteria for assignment of bacterial species established by Roselló Mora [80], based on 16S-rRNA identity percentage (>97%). We proposed that four isolated species were designated as M. odoratimimus, while the strains C2723, C1519 and C4067 may be cataloged as new species of Myroides. The phylogenetic evidence as a robust tool for identification supports our predictions. Nonetheless, further studies based on a more rigorous genome-based phylogenetic analysis are needed to validate our hypothesis. Due to the broad AMR spectrum observed in the isolates of study, we decided to identify the ARE presumptively involved in pan-drug resistance. For instance, previous reports describe that M. odoratimimus may harbor up to 32 AMR genes [32, 81, 82] of which ß-lactamases and efflux pumps are the most abundant AREs observed. From 2014 until now, the main AREs identified for Myroides spp., has been the following: ß-lactamases: blaVIM, blaIMP, blaNMD, blaOXA-78, blaOXA-209, blaOXA-347, blaKPC, blaTUS, blaEBR-1, blaMOC and blaMUS-1; tetracycline resistance: tet(X6); efflux pumps: abeS, msrB, qacH, rosA; macrolides: erm(F), ere(D) [12, 32, 55, 83–85]. Here, we were able to detect the AREs aforementioned; however, it is important to highlight that the isolates analyzed in this work also displayed AREs and a phenotype associated with resistance to colistin, glycopeptides and rifampicin, a resistance trait not observed previously. These results suggest that the resistome of Myroides spp. is expanding remarkably, and probably soon the species of this genus might convert into an important health threat. Other important trait is that multidrug resistance genotype was observed in the presumptive new species, although only M. orodatimimus, M. odoratus, M. phaeus and M. injerensis have been cataloged as relevant AMR pathogens [45, 57, 82, 83], our results indicate that the multidrug resistance phenotype possibly is highly expanded and extended in several species of Myroides. In the case of M. orodatimimus a chromosomic metallo ß-lactamase has been describe, the MUS-1 [86]. Two strains had an undetermined phenotype, however carrier, this due the phenotypic assay is not validated for bacteria different to Enterobacterales or Pseudomonas spp, Pathogen Myroides species have been shown to possess a number of VF that are associated with a range of processes, including cell adherence, intracellular survival, and capsule production [32, 82]. Nevertheless, a more comprehensive investigation into the molecular mechanisms underlying the pathogenicity of Myroides spp. has yet to be conducted. Therefore, the current state of knowledge regarding the infection process and disease-causing mechanisms of Myroides is limited. Based on the identified VF, the results suggest that the isolates under study possess the ability to survive and replicate within host cells, evade phagocytic cells of the immune system, and are able to cause disease. This is a virulence trait observed in other opportunistic pathogens, including Mycobacterium spp., Pseudomonas spp., Serratia spp., and others [87–89]. Certainly, our work has limitations, design nature without doubts since is centered only the background of clinical strains of Myroides spp., the number of strains included, in this sense information about prevalence around the world is limited beside we included all references published. The correlation with a in vivo model could evaluate the impact of virulence factors and the need of phenotypic methods to explore the activity of carbapenemases in this genus. Conclusions The Myroides genus is a rare microorganism that can cause infections in both immunosuppressed and immune competent hosts. The outcome of infection varies depending on the antimicrobial profile of the bacteria. Molecular techniques are essential for accurately identifying these bacteria, characterizing potential species, and exploring therapeutic options for achieving clearance of infections. More studies are needed to prove that strains C2723, C1519 and C4067 are new species within the Myroides genus. Finally, the species analyzed in the present work showed reduced susceptibility patterns for aminoglycosides, ß-lactams, cyclic lipopeptides, this was corroborated with the genes found in the genome, therefore, susceptibility tests should be performed in the clinical microbiology laboratory and the Infectious diseases specialists staff should consider these susceptibility patterns for the treatment scheme of patients suffering infections by microorganisms of this genus. Supporting information CARBA NP in Myroides spp. clinical strains. (DOCX) Plasmids extracted from Myroides spp. clinical strains. MWM: Molecular weight marker. (DOCX) Plasmids extracted from Myroides spp. clinical strains. MWM: Molecular weight marker. (Raw data, letters were added with the transilluminator software). (DOCX) 17 Jul 2024 PONE-D-24-22192Myroides species, pathogenic spectrum and clinical microbiology sight in Mexican isolates.PLOS ONE Dear Dr. Lopez Jacome, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 31 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Mabel Kamweli Aworh, DVM, MPH, PhD. FCVSN Academic Editor PLOS ONE Journal requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. 3. We notice that your supplementary figures are uploaded with the file type 'Figure'. Please amend the file type to 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: In addition to addressing all the comments of the reviewers' kindly address the following; 1. Lines 120-124: Please provide the range of concentrations for each antimicrobial tested. 2. Lines 362–368: This is not clear. Please rewrite for clarity and flow. 3. Highlight the key limitations of the present study in the last paragraph of the discussion section. 4. In your conclusion, can you provide some recommendations based on your study findings? [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This is a good manuscript with impressive efforts from the authors. A couple of areas require further clarification and possible additions line 48 - The introduction in the abstract does not clearly state the significance of this study. What is the public health impact of understanding the pathogenic spectrum or clinical microbiology of Myroides species in Mexico? This needs to be clearly stated here. line 55 - Indicate the study design that was used here. Was this a retrospective analysis? Also, indicate the period of the specimen was collection. This makes the methods clearer line 57 - include total number of myroides isolates recovered or used and the percentage of species of particular type line 58 - This statement makes it look like you identified only 6 instead of 7 strains highlighted in the main paper. can you clarify? line 61 - Are we implying that 100% of isolates were resistant to all these antibiotics mentioned? Its not very clear from this sentence. If other otherwise, please state what percentage of isolates were resistant to antibiotic A and what percentage was resistant to antibiotic B e.t.c line 96 - It will be interesting to know, any specific concerns or knowledge gaps regarding Myroides species in Mexico? Are there any existing studies on their prevalence or clinical impact in this region? it is not clear if you have done an effective review of relevant existing literature on Myroides species and their clinical significance, particularly in a Mexican context. lines 102 - 190 - No ethical considerations were mentioned in the methods. Were there any ethical considerations related to the use of clinical specimens? lines 102 - 190 - what data collection/recording tool was used to collect or record the data on characteristics of patients e.g Gender, Age, Comorbidities, Type of infection, Clinical sample Isolation, Date Treatment Outcome e.t.c? Did you use a proforma? was this a standard tool? I cant seem to find any details in the methods for this. please indicate line 205 - Table 1 - Considering that this study has to do with Myroides species which are typically found in immunocompromised hosts, did you consider collecting or recording data on the immune status of the patients? I know you had a lot of burns patients. But could the this have anything to do with the treatment and outcome of these patients outlined in table 1? lines 306 - 368 - what are the limitations of this study? I am not able to clearly see where you highlighted the limitations. Since the phenotypic assay you used is not validated for the specific microorganisms tested (outside of Enterobacterales and Pseudomonas aeruginosa), can you elaborate on the potential limitations of using this assay for these particular strains? - For strains C1996 and C4256 with 16 mm halos, which falls under the inconclusive range according to CLSI M100 for Enterobacterales and Pseudomonas aeruginosa, how do you plan to address this inconclusiveness? Are there any additional confirmatory tests planned to definitively determine the presence or absence of carbapenemase activity in these strains? - Given the limitations of the current assay, would exploring alternative methods for carbapenemase detection, such as molecular techniques (e.g., PCR), be a valuable addition to strengthen the study's findings? - Can you suggest any modifications or optimizations to the current phenotypic assay that might improve its applicability to a broader range of microorganisms? How do you plan to address the limitations of the current approach in future studies investigating carbapenemase activity in these specific microorganisms? Reviewer #2: The authors described intelligently the materials and methods used in the research. The research results were reported with clarity devoid of ambiquity. Areas of further research need to be succintly stated under the conclusion section in the manuscript. There are mentions of additional research in the manuscript in line 337 - 338 and 362-363; authors are advised to state them in the conclusion section. Authors should provide study limitations in the manuscript A typo/unclear statement in line 371. Authors are advised to edit this typographical error. Reviewer #3: Myroides species, pathogenic spectrum and clinical microbiology sight in Mexican isolates. Reviewer’s comments • The Introduction was well-written with clear objectives, the gap identified and appropriate links given. • The Methods used were appropriate for the set objectives. • The results were accurately presented and the discussion derived from the findings and reasonable inference drawn. • The analysis of the results were scientific and exact. Accept after minor revisions. Lines 137-149 Author should cite a reference for the method used for whole genome sequencing. Lines 150-156 • Authors should cite a reference for the method used here too. • Methods should be well cited. Lines 371-371 • Myroides genus is not such as uncommon microorganism causing infections, both in • immunosuppressed and immune competent hosts, with different outcomes depending on • antimicrobial profiles. WHY NOT SAY: Myroides genus is a common microorganism causing... Page 7-40 • Numbering is not appropriate. Need to check the numbering and number the required lines appropriately. Page 15 • Are there more specific ways to itemize the data availability Statement. • Ensure regular spacing through the write up. In conclusion, authors should identify any limitations to the execution of the research as this is necessary and obvious going by the methods used. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Abdulhakeem Abayomi Olorukooba Reviewer #2: No Reviewer #3: Yes: Taiwo Akindahunsi ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. Submitted filename: PONE-D-24-22192 reviewed_olorukooba.pdf 12 Aug 2024 Rebuttal letter First of all, we would like to thank the reviewers for their time and comments on this paper. Reviewer 1. Line 48 - The introduction in the abstract does not clearly state the significance of this study. What is the public health impact of understanding the pathogenic spectrum or clinical microbiology of Myroides species in Mexico? This needs to be clearly stated here. Thanks a lot for the comment, we have added the next to your consideration. “In addition, their pathogenic role is limited in terms of reporting their microbial physiology, so the present work provides information in this regard in addition to the information that is available in the international literature.” In this sense, information in our work will not be exclusive to the Mexican microbiological community, but will give evidence to the international scientific community on aspects of susceptibility and virulence factors. Line 55 - Indicate the study design that was used here. Was this a retrospective analysis? Also, indicate the period of the specimen was collection. This makes the methods clearer. Line 57 - include total number of myroides isolates recovered or used and the percentage of species of particular type Complete description about the time period was mentioned at material and methods, however, thanks to your observation we have added “Methods: Seven Myroides spp., strains associated with infections were included from 1/January/2012 to 1/January/20 and identified by miniaturized biochemistry and MALDI-ToF”. Line 58 - This statement makes it look like you identified only 6 instead of 7 strains highlighted in the main paper. can you clarify? I so sorry about that, We have added the number of strains, were in total 7, as is mentioned in objective, and methods. Sorry for the confusion. Line 61 - Are we implying that 100% of isolates were resistant to all these antibiotics mentioned? Its not very clear from this sentence. If other otherwise, please state what percentage of isolates were resistant to antibiotic A and what percentage was resistant to antibiotic B e.t.c. Thank you very much for your kind and proper observation. Resistance leve lis mentioned in results due the characters numbers for abstract. However, we added the next: against these antibiotics (AK and GN both 100%, ATM, CAZ and FEP 100%, e.g.); moreover, the presences of carbapenemases were evidenced by meropenem (mCIM) and imipenem (CARBA NP) degrading activity in six isolates and” Thank you. Line 96 - It will be interesting to know, any specific concerns or knowledge gaps regarding Myroides species in Mexico? Are there any existing studies on their prevalence or clinical impact in this region? it is not clear if you have done an effective review of relevant existing literature on Myroides species and their clinical significance, particularly in a Mexican context This is a very important comment and thank you very much for your question. There is no information about prevalence in our country o region, as we mentioned in Discussion, we performed research on pubmed since 2020 and we just found 43 papers related with Myroides causing infection and all those papers were properly cited in our work, besides the most of those Works are case reports, in our knowledge (with humility) this is the first in our country. Lines 102 - 190 - No ethical considerations were mentioned in the methods. Were there any ethical considerations related to the use of clinical specimens? Thank you for this observation, we only used strains, and was conducted according to research acceptance with assigned ID 55/22 AC from our institution. Lines 102 - 190 - what data collection/recording tool was used to collect or record the data on characteristics of patients e.g Gender, Age, Comorbidities, Type of infection, Clinical sample Isolation, Date Treatment Outcome e.t.c? Did you use a proforma? was this a standard tool? I cant seem to find any details in the methods for this. please indicate Data requested is from electronical record and it is mentioned in table 1. Proforma was not used. Line 205 - Table 1 - Considering that this study has to do with Myroides species which are typically found in immunocompromised hosts, did you consider collecting or recording data on the immune status of the patients? I know you had a lot of burns patients. But could the this have anything to do with the treatment and outcome of these patients outlined in table 1? Actually this a great idea and research question for future studies, but due to the nature of design we want to know about the genetic background of Myroides, what if more microbiologist isolate this bacteria and to decide give certain antibiotics, if we give information about resistance genes, susceptibility behavior could support microbiologist and infectious diseases specialist, probably in other kind of patients or institutions this bacteria are mos frequent that with us, we don’t know about that. Then immunocompromised status and those factors that may influence host vulnerability was not explored. Not in this time. lines 306 - 368 - what are the limitations of this study? I am not able to clearly see where you highlighted the limitations. About this point we have added the next: Certainly, our work has limitations, design nature without doubts since is centered only the background of clinical strains of Myroides spp., the number of strains included, in this sense information about prevalence around the world is limited beside we included all references published. The correlation with a in vivo model could evaluate the impact of virulence factors and the need of phenotypic methods to explore the activity of carbapenemases in this genus. Since the phenotypic assay you used is not validated for the specific microorganisms tested (outside of Enterobacterales and Pseudomonas aeruginosa), can you elaborate on the potential limitations of using this assay for these particular strains? Was added according to your proper recommendation. the need of phenotypic methods to explore the activity of carbapenemases in this genus. - For strains C1996 and C4256 with 16 mm halos, which falls under the inconclusive range according to CLSI M100 for Enterobacterales and Pseudomonas aeruginosa, how do you plan to address this inconclusiveness? Are there any additional confirmatory tests planned to definitively determine the presence or absence of carbapenemase activity in these strains? Thank you very much, and again thanks to your comments we decided to include another experiment in order to prove the carbapenemase activity, in this case we change the substrate (IMP instead up MEM) and the used was CARBA NP. We added the next. Line 136 Due this method is validated just for Enterobacterales and Pseudomonas aeruginosa, a second method was performed, CARBA NP, also referred in CLSI M100 2023, briefly, two 600 µL conic tubes were labelled for each strain tested, then 100 µL of protein extraction buffer were added to each tube (a and b) and vortexed for 5 seconds and subsequently 100 µL of solution A (without IMP as substrate) and B (supplemented with IMP as substrate to carbapenemase) were added to the respective tubes labelled and again vortexed and incubated at 35° C/2 hours. Positive tests showed a change in color (yellow as positive and unchanged as negative). E. coli ATCC 25922 was used as negative control and K. pneumoniae ATCC BAA-1705 as positive control. The interpretation of the test was according to CLSI M100 2023 [19]. And Line 242 However with CARBA NP strain C1996 was interpreted as positive as well as C4256., Previously C4067 was defined to be negative with mCIM however, once repeated with CARBA NP was defined as positive. - Given the limitations of the current assay, would exploring alternative methods for carbapenemase detection, such as molecular techniques (e.g., PCR), be a valuable addition to strengthen the study's findings? About this comment, actually is not necesary since our work included whole genoma sequencing and the look and informatiojn about resistome was presented and included in fig and text. However, we decided to prove it with CARBA NP as you recommeded. - Can you suggest any modifications or optimizations to the current phenotypic assay that might improve its applicability to a broader range of microorganisms? How do you plan to address the limitations of the current approach in future studies investigating carbapenemase activity in these specific microorganisms? This can be carried on in future studies, no doubt that changes can be performed. Thank you. We want to say you thank you for your time and effort. Reviewer #2: Thank you very much for your comments. There are mentions of additional research in the manuscript in line 337 - 338 and 362-363; authors are advised to state them in the conclusion section. We want to thank you about this observation we added the next in Conclusions “More studies are needed to prove that strains C2723, C1519 and C4067 are new species within the Myroides genus.” Authors should provide study limitations in the manuscript Thank you for the advice, we have added this one as “Certainly, our work has limitations, design nature without doubts since is centered only the background of clinical strains of Myroides spp., the number of strains included, in this sense information about prevalence around the world is limited beside we included all references published. The correlation with a in vivo model could evaluate the impact of virulence factors and the need of phenotypic methods to explore the activity of carbapenemases in this genus” A typo/unclear statement in line 371. Authors are advised to edit this typographical error. Thank you so much for your kind revision, advice and support, we have changed to The Myroides genus is a rare microorganism that can cause infections in both immunosuppressed and immune competent hosts. The outcome of infection varies depending on the antimicrobial profile of the bacteria. Molecular techniques are essential for accurately identifying these bacteria, characterizing potential species, and exploring therapeutic options for achieving clearance of infections. Thank you so much for everything. Reviewer #3: Lines 137-149. Author should cite a reference for the method used for whole genome sequencing. Thank you so much for, we looked for how to cite, and in several papers describe the procedure according to manufacturer, however, we include reference, number 15. Lines 150-156 • Authors should cite a reference for the method used here too. • Methods should be well cited. Citation was done. Thank you for the advice. Lines 371-371 • Myroides genus is not such as uncommon microorganism causing infections, both in • immunosuppressed and immune competent hosts, with different outcomes depending on • antimicrobial profiles. WHY NOT SAY: Myroides genus is a common microorganism causing... Thank you, change was done as following: The Myroides genus is a rare microorganism that can cause infections in both immunosuppressed and immune competent hosts. The outcome of infection varies depending on the antimicrobial profile of the bacteria. Molecular techniques are essential for accurately identifying these bacteria, characterizing potential species, and exploring therapeutic options for achieving clearance of infections.. More studies are needed to prove that strains C2723, C1519 and C4067 are new species within the Myroides genus. Page 15 • Are there more specific ways to itemize the data availability Statement. • Ensure regular spacing through the write up. In conclusion, authors should identify any limitations to the execution of the research as this is necessary and obvious going by the methods used. About numeration I´ll check it in the page when we generate the PDF, thank you. About the ways more specific, I really Will appreciate if you help me with this point for future Works, thank you for you support. I´ll check the spaces. Thank you for your time, kindness, support and advices. We really appreciate it. Editor Comments: Thank you very much for your comments. 1. Lines 120-124: Please provide the range of concentrations for each antimicrobial tested. Thank you. We have added For AK, GN, ATM, CAZ and FEP concentrations tested were from 256 µg/mL to 0.25 µg/m, while for CIP, LVX, MEM, IMP, AZT, E, DOX, and TYG concentrations were 64 µg/mL to 0.0612 µg/mL. On the other hand for COL and TZP were 128 µg/mL to 0.125 µg/mL and 128/4 µg/mL to 0.125/4 µg/mL respectively. Finally, SXT starting concentration 8/152 µg/mL to 0.00078/0.1484 µg/mL. Lines 362–368: This is not clear. Please rewrite for clarity and flow. Thanks a lot for your advice. Change was made according recommendation as follow: Pathogen Myroides species have been shown to possess a number of VF that are associated with a range of processes, including cell adherence, intracellular survival, and capsule production. Nevertheless, a more comprehensive investigation into the molecular mechanisms underlying the pathogenicity of Myroides spp. has yet to be conducted. Therefore, the current state of knowledge regarding the infection process and disease-causing mechanisms of Myroides is limited. Based on the identified VF, the results suggest that the isolates under study possess the ability to survive and replicate within host cells, evade phagocytic cells of the immune system, and are able to cause disease. This is a virulence trait observed in other opportunistic pathogens, including Mycobacterium spp., Pseudomonas spp., Serratia spp., and others Highlight the key limitations of the present study in the last paragraph of the discussion section. Thank you, limitations were added. Certainly, our work has limitations, design nature without doubts since is centered only the background of clinical strains of Myroides spp., the number of strains included, in this sense information about prevalence around the world is limited beside we included all references published. The correlation with a in vivo model could evaluate the impact of virulence factors and the need of phenotypic methods to explore the activity of carbapenemases in this genus. In your conclusion, can you provide some recommendations based on your study findings? Thank you, we added the next “Finally, the species analyzed in the present work showed reduced susceptibility patterns for aminoglycosides, ß-lactams, cyclic lipopeptides, this was corroborated with the genes found in the genome, therefore, susceptibility tests should be performed in the clinical microbiology laboratory and the Infectious diseases specialists staff should consider these susceptibility patterns for the treatment scheme of patients suffering infections by microorganisms of this genus”. We would like to thank all the reviewers for their time, kindness and advice, which will enrich our work. Thank you very much for your time, kindness and advice, which will allow us to enrich our work. Submitted filename: Response to Reviewer.docx 28 Aug 2024 Myroides species, pathogenic spectrum and clinical microbiology sight in Mexican isolates. PONE-D-24-22192R1 Dear Dr. Jacome, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Mabel Kamweli Aworh, DVM, MPH, PhD. FCVSN Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Authors have addressed all my concerns and i do not have any other concerns with this submission. Great Job Reviewer #2: The authors have responded appropriately to the suggested recommendations and corrections have been effected. The manuscript is technically sound and presented in an intelligible fashion. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Abdulhakeem Abayomi Olorukooba Reviewer #2: Yes: Olubunmi Margaret Ogbodu ********** 2 Sep 2024 PONE-D-24-22192R1 PLOS ONE Dear Dr. López-Jácome, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Mabel Kamweli Aworh Academic Editor PLOS ONE